Grazoprevir/Elbasvir, Merck's Investigational Chronic Hepatitis C Therapy, Granted FDA Breakthrough Therapy Designations; New Phase 2, 3 Data in Multiple HCV Patient Types Will Be Presented At The International Liver Congress TM 2015